Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACK: Trelagliptin vs Alogliptin in T2DM
NCT02771093Phase 4Completed
- Sponsor
- Takeda
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Standard Deviation of 24-hour Blood Glucose Values at 28 days. Started Sep 2016; status: completed.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02771093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771093.